文献速递淋巴瘤

低剂量FCR一线治疗老年/合并症CLL/SLL的长期结果

Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
PubMed 文献 · Br J Haematol · 2021-02-22

捷克CLL研究组开展前瞻性观察研究,纳入107例不适合全剂量FCR的初治老年/合并症CLL/SLL患者,中位年龄70岁。低剂量FCR耐受性良好,中位无进展生存29个月,IGHV突变患者达53个月,无del 11q或17p者达74个月。

要点

  • 低剂量FCR对选定老年/合并症CLL/SLL患者是耐受良好且有效的一线方案。
  • 3-4级中性粒细胞减少发生率56%,但严重感染仅15%。
  • IGHV突变且无del 11q或17p者中位无进展生存达74个月。

核心结论

  • 低剂量FCR对生物学预后良好的选定老年/合并症CLL/SLL患者是耐受良好且有效的一线方案。

研究设计与样本

  • 捷克CLL研究组开展的前瞻性观察研究,2009年3月至2012年7月纳入107例不适合全剂量FCR的初治老年/合并症CLL/SLL患者。
  • 患者中位年龄70岁,中位CIRS评分5,中位肌酐清除率69 ml/min。

主要发现

  • 77%患者具有不利生物学预后,其中IGHV未突变74%,del 17p占9%。
  • 3-4级中性粒细胞减少发生率为56%,严重感染发生率为15%。
  • 中位无进展生存为29个月,IGHV突变患者为53个月,无del 11q或17p者为74个月。

关键数值与推荐

  • 氟达拉滨减至12 mg/m2静脉或20 mg/m2口服,第1-3天;环磷酰胺减至150 mg/m2静脉/口服,第1-3天。

临床怎么用

  • 对不适合全剂量FCR的老年/合并症CLL/SLL患者,可考虑低剂量FCR一线治疗,尤其IGHV突变且无del 11q或17p者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic options used to be very limited for treatment-naïve elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) before the introduction of chemo-immunotherapy. Because dose-reduced fludarabine-based regimens yielded promising results, the Czech CLL Study Group initiated a prospective observational study to assess safety and efficacy of low-dose fludarabine and cyclophosphamide combined with rituximab (FCR) in elderly/comorbid patients. Between March 2009 and July 2012, we enrolled 107 patients considered ineligible for full-dose FCR (median age, 70 years; median Cumulative Illness Rating Scale score, 5; median creatinine clearance, 69 ml/min). Notably, 77% patients had unfavourable biological prognosis [unmutated immunoglobulin heavy-chain variable-region gene (IGHV), 74%; deletion 17p, 9%). Fludarabine was reduced to 12 mg/m2 intravenously (iv) or 20 mg/m2 orally on days 1-3 and cyclophosphamide to 150 mg/m2 iv/orally on days 1-3. Grade 3-4 neutropenia occurred in 56% of the patients, but there were serious infections in only 15%. The median progression-free survival was 29 months, but was markedly longer in patients with mutated IGHV (median 53 months), especially in absence of del 11q or 17p (median 74 months). Low-dose FCR is a well-tolerated and effective first-line regimen for selected elderly/comorbid patients with CLL/SLL with favourable biology. The study was registered at clinicaltrials.gov (NCT02156726).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Smolej L, Brychtová Y, Cmunt E, et al. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group. Br J Haematol. 2021. PMID: 33618437. doi:10.1111/bjh.17373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。